Clinical Trials Logo

Colorectal Neoplasms clinical trials

View clinical trials related to Colorectal Neoplasms.

Filter by:

NCT ID: NCT05653960 Not yet recruiting - Colorectal Cancer Clinical Trials

Clinical Outcomes After EMR or ESD of Colorectal Neoplasms - A Multicenter Registry

Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

This study aims to establish a multicenter registry platform to capture clinical data from subjects undergoing colorectal EMR and ESD.

NCT ID: NCT05652894 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Start date: December 20, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).

NCT ID: NCT05636085 Not yet recruiting - Colorectal Cancer Clinical Trials

Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma

reconAAsense
Start date: June 1, 2023
Phase:
Study type: Observational

This study is to determine how the Mainz Biomed Colorectal Cancer Screening Test works when used in people aged ≥45 years of age and at an average risk of developing colorectal cancer.

NCT ID: NCT05634590 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Start date: December 2022
Phase: Phase 2
Study type: Interventional

RAS mutations are found in nearly half of colorectal cancer patients. However, there is no targeted driver gene drugs have been approved for RAS-mutated patients. For RAS mutant metastatic colorectal cancer, the commonly used treatment regimen is bevacizumab combined with chemotherapy.

NCT ID: NCT05630794 Not yet recruiting - Clinical trials for Colorectal Carcinoma

Testing ONC201 to Prevent Colorectal Cancer

Start date: October 8, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety, side effects, and best dose of Akt/ERK Inhibitor ONC201 (ONC201) in preventing colorectal cancer in patients with familial adenomatous polyposis (FAP) or a history of multiple polyps. ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT05588297 Not yet recruiting - Clinical trials for Colorectal Cancer Liver Metastases

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Start date: October 2022
Phase: Phase 2
Study type: Interventional

This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients

NCT ID: NCT05587088 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)

PA001
Start date: December 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II clinical study that has two phases. In phase Ib, the safety evaluation of the extract of Petiveria alliacea (Esperanza) will be carried out in patients with metastatic gastrointestinal tumors (colon, pancreas, stomach, and biliary tract) and patients with newly diagnosed and relapsed acute leukemia. In phase IIb, the safety will continue to be evaluated, and the efficacy of the Esperanza extract will be explored in combination with chemotherapy in patients with metastatic gastrointestinal tumors (colon, pancreas, stomach, and biliary tract) with newly diagnosed acute leukemias and relapses.

NCT ID: NCT05585814 Not yet recruiting - Clinical trials for Locally Advanced Colorectal Cancer

Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer

COBP
Start date: October 2022
Phase: Phase 2
Study type: Interventional

This prospective, single-arm study aims to investigate the safety and efficacy of pembrolizumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS locally advanced colorectal cancer patients

NCT ID: NCT05584540 Not yet recruiting - Colorectal Cancer Clinical Trials

UNTIRE: Cancer-related Fatigue With Digital Treatment

Start date: August 30, 2024
Phase: N/A
Study type: Interventional

This research is being done to find out if using a smartphone app as digital treatment to reduce Cancer Related Fatigue is feasible and easy to use. This research study is evaluating a smartphone application named the "Untire" app. The Untire app was designed as a digital treatment plan for people experiencing Cancer Related Fatigue (CRF).

NCT ID: NCT05577143 Not yet recruiting - Cancer Colorectal Clinical Trials

Blood Screening for Adult Colorectal Cancer

BACCHUS
Start date: October 2022
Phase:
Study type: Observational

Multicenter, inter-regional, case-control study with the primary objective of evaluating the discriminative power of the blood biomarker TFPI-1 to separate patients with histologically proven CRC from an asymptomatic control population between 50 and 75 years of age with normal colonoscopy.